Search

Displaying results 1221 - 1230 of 5261 in total
  1. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

  2. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis. … [L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis

  3. Drug

    Telithromycin

    go.drugbank.com/drugs/DB00976
    Approved

    Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. … Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one.

  4. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance.

  5. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  6. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
  7. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.

  8. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

  9. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C).

    Synonyms: N-(n-Butyl)deoxynojirimycin, NB-DNJ
  10. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.